

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2019

(Rs. in Lakhs)

Particulars	Quarter Ended			Year Ended
	3 months ended 30.06.19	Preceding 3 months ended 31.03.19	Corresponding 3 months ended 30.06.18	31.03.2019
	(Unaudited)	(Audited) (Refer Note no. 2)	(Unaudited)	(Audited)
Income				
1 Revenue from operations	78802	75122	73565	312853
2 Other income	3054	5246	1778	10148
3 Total Income (1+2)	81856	80368	75343	323001
Expenses				
(a) Cost of materials consumed	16904	16825	17848	68207
(b) Purchases of stock-in-trade	29895	10018	12755	64589
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(13720)	3666	1071	2557
(d) Employee benefits expense	14281	14614	12598	53720
(e) Finance costs	93	8	20	55
(f) Depreciation and amortisation expense	1906	1368	1136	4859
(g) Other expenses	14894	13636	15256	63132
4 Total expenses	64253	60135	60684	257119
5 Profit before exceptional items and tax (3-4)	17603	20233	14659	65882
6 Exceptional items [credit / (charge)] net	-	(317)	(828)	489
7 Profit before tax (5+6)	17603	19916	13831	66371
8 Tax expense				
(a) Current tax	5641	2815	4470	19282
(b) Deferred tax	616	4798	502	4553
9 Profit for the period/year (7-8)	11346	12303	8859	42536
10 Other comprehensive income				
(i) Items that will not be reclassified to profit or loss	-	(85)	-	(844)
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	78	-	295
11 Total comprehensive income for the period (9+10)	11346	12296	8859	41987
Paid-up equity share capital (face value per share Rs. 10)	16941	16941	8470	16941
Other equity				197301
Earnings per share (EPS) (of Rs. 10 each)				
Basic and diluted EPS (Rs.) (Refer Note 4)	6.70	7.26	5.23	25.11
	Not Annualised			

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 22nd
- The figures for the preceding three months ended 31st March, 2019 are the balancing figures between the audited financial results for the year ended 31st March, 2019 and the year to date figures upto the third quarter for the nine months ended 31st December, 2018.
- Effective 1st April, 2019, the Company adopted Ind AS 116 "Leases" and applied the same to the lease contracts existing on 1st April, 2019 using the modified retrospective approach, recognizing right-of-use asset and adjusted lease liability. Accordingly, comparatives for the year ended 31st March, 2019 and other periods disclosed have not been retrospectively adjusted. The effect of the adoption is not significant to the profit for the period.
- The Company had allotted 8,47,03,017 fully paid up equity shares of Rs.10/- each during the quarter ended 30th September, 2018 pursuant to a bonus issue in 1:1 ratio approved by the shareholders through postal ballot. The bonus shares were issued by capitalisation of profits transferred from general reserve. Record date fixed by the Company was 13th September, 2018. The earnings per share have been adjusted for previous period presented in accordance with Ind AS 33 Earnings per share.
- In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a limited review of the standalone financial results for the quarter ended 30th June, 2019.
- The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.
- Other expenses for the quarter includes Rs. 581 Lakhs on account of provisions for VAT assessments.
- Previous periods' figures have been re-grouped / re-classified wherever necessary.

By Order of the Board


Annaswamy Vaidheesh
Managing Director
DIN: 01444303

22nd July, 2019